Articles published by Gilead Sciences, Inc.
![](https://mms.businesswire.com/media/20240620044585/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240614729632/en/836069/5/NEW_KITE_COLOR_LOGO.jpg)
![](https://mms.businesswire.com/media/20240606954431/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240604334684/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240603095365/en/836069/5/NEW_KITE_COLOR_LOGO.jpg)
![](https://mms.businesswire.com/media/20240603718191/en/836069/5/NEW_KITE_COLOR_LOGO.jpg)
![](https://mms.businesswire.com/media/20240531380992/en/2147242/5/ARCUS_Logo_RGB_1920x1080.jpg)
![](https://mms.businesswire.com/media/20240531335673/en/2147237/5/ARCUS_Logo_RGB_1920x1080.jpg)
![](https://mms.businesswire.com/media/20240530725767/en/778437/5/GCP_Primarylarge_1.jpg)
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
May 31, 2024
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20240530516266/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240522704668/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240518003116/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240514656201/en/836069/5/NEW_KITE_COLOR_LOGO.jpg)
![](https://mms.businesswire.com/media/20240509189414/en/836069/5/NEW_KITE_COLOR_LOGO.jpg)
Via Business Wire
![](https://mms.businesswire.com/media/20240506028033/en/836069/5/NEW_KITE_COLOR_LOGO.jpg)
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
May 07, 2024
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20240430344533/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead Sciences to Present at Upcoming Investor Conferences
April 30, 2024
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20240426676086/en/778437/5/GCP_Primarylarge_1.jpg)
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20240425746971/en/778437/5/GCP_Primarylarge_1.jpg)
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20240408350262/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
April 08, 2024
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20240327502740/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240328734624/en/2082732/5/Xilio_Full_CLR_Logo_CMYK_%5Bwith_registered_mark%5D.jpg)
![](https://mms.businesswire.com/media/20240311327601/en/778437/5/GCP_Primarylarge_1.jpg)
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
March 11, 2024
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20240306036015/en/778437/5/GCP_Primarylarge_1.jpg)
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
March 06, 2024
Via Business Wire
Tickers
GILD
![](https://mms.businesswire.com/media/20240305598604/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240306606452/en/2055933/22/Logo_Merus_CMYK_Blue_1000x280.jpg)
![](https://mms.businesswire.com/media/20240304530607/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240304716860/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240227849231/en/778437/5/GCP_Primarylarge_1.jpg)
![](https://mms.businesswire.com/media/20240226441430/en/778437/5/GCP_Primarylarge_1.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.